Moleculin Biotech Inc/ US60855D3098 /
2024-05-02 9:51:37 PM | Chg. +0.0900 | Volume | Bid1:46:37 AM | Ask1:46:37 AM | High | Low |
---|---|---|---|---|---|---|
5.1500USD | +1.78% | 5,690 Turnover: 19,282.1970 |
5.1600Bid Size: 500 | 5.3900Ask Size: 400 | 5.3599 | 5.1096 |
GlobeNewswire
2021-03-10
Roth Capital Partners 33rd Annual Conference to be held Virtually March 15-17, 2021
GlobeNewswire
2020-06-29
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
GlobeNewswire
2020-06-23
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
GlobeNewswire
2020-04-29
WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial
GlobeNewswire
2020-04-21
WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQ...
GlobeNewswire
2020-04-16
WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 ...
GlobeNewswire
2020-04-09
WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replicati...
GlobeNewswire
2020-04-01
WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board
GlobeNewswire
2020-03-30
Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing
GlobeNewswire
2020-03-24
Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020
GlobeNewswire
2020-03-24
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other ...
GlobeNewswire
2020-03-19
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS
GlobeNewswire
2020-03-16
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE
GlobeNewswire
2020-03-13
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE
GlobeNewswire
2020-03-11
WPD PHARMACEUTICALS RECEIVED $800,000 REIMBURSEMENT FROM $7.4 MILLION GOVERNMENT GRANT FOR DEVELOPME...
GlobeNewswire
2020-03-04
WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance
GlobeNewswire
2020-02-27
WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in ...
GlobeNewswire
2020-02-24
WPD Pharmaceuticals Granted Key Patent Exclusively Licensed From Wake Forest University